Clinical trials: HIV-1 Infection, open to volunteers
HIV/AIDS
Simplified Treatment of Anti-retrovirus in China (C-STAR)
To observe the efficacy and safety of simplified therapy regimen for treating with HIV-1 infected patients in Chinese real word.
- Trial name
- NCT03603977
- Testing
- Lpv/r+3TC
- Where
- China
- Volunteers
- 600 people
- Sponsor
- Guangzhou 8th People's Hospital
HIV Infections
HIV-1 Infected Patients, Phase II Trial, Dual Combination Doravirine/Raltegravir Open Label
The objective of antiretroviral therapy (ART) is the maintenance of HIV viral suppression, the optimal condition to prevent disease progression, to optimize immune restoration, to prevent the development of viral resistance and…
- Trial name
- DORAL (NCT04513626)
- Testing
- DORAVIRINE 100 MG [Pifeltro]
- Where
- France
- Volunteers
- 150 people
- Sponsor
- Centre de Recherches et d'Etude sur la Pathologie Tropicale et le Sida
HIV/AIDS and Infections
Phase II Trial of ART + Dual bNAbs vs. ART + Placebo During Primary HIV-1 Infection-impact on Post-ART Control
RHIVIERA-02 trial is a placebo-controlled double-blinded two arm prospective phase II trial. This study will test the use of broadly neutralising antibodies (bNAbs) in participants, at primary HIV infection (PHI) and ART…
- Trial name
- RHIVIERA-02 (NCT05300035)
- Testing
- Recombinant human monoclonal antibody (bNAbs)
- Where
- 17 sites in France
- Volunteers
- 69 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV -1 Infection
Cabotegravir & Rilpivirine Antiretroviral Therapy in Pregnancy
Phase IV, multi-site, open-label, non-randomized study of the pharmacokinetics (PK) of long-acting injectable cabotegravir and rilpivirine (CAB LA + RPV LA) during pregnancy and postpartum.
- Trial name
- CREATE (NCT07637942)
- Testing
- Every 4-week long-acting injectable cabotegravir and rilpivirine
- Where
- 10 sites in United States
- Volunteers
- 40 people
- Sponsor
- International Maternal Pediatric Adolescent AIDS Clinical Trials Group
Depression, HIV-1-infection
Treatment Research Investigating Depression Effects on Neuroimmune Targets (TRIDENT)
The purpose of this randomized controlled trial is to understand how a cognitive-behavioral treatment (a form of psychological treatment) for depression changes the gut microbiome (micro-organisms that regulate the health of the…
- Conditions
- Depression, HIV-1-infection, Inflammation
- Trial name
- TRIDENT (NCT05136703)
- Testing
- Cognitive-Behavioral Therapy for Adherence and Depression (CBT-AD), Antiretroviral Therapy (ART) Adherence Counseling
- Where
- 2 sites in United States
- Volunteers
- 150 people
- Sponsor
- Florida International University
HIV -1 Infection, Methamphetamine Use
Short-term Effects of Methamphetamine on Residual Latent HIV Disease Study
The most commonly used illicit stimulant in people with HIV (PWH) is methamphetamine (MA). Prior studies demonstrate strong evidence that MA promotes increased HIV transcription as well as immune dysregulation.
- Trial name
- EMRLHD (NCT07584369)
- Testing
- Oral Methamphetamine
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- University of California, San Francisco
HIV -1 Infection
Early Neutralizing Antibodies in Infants Living With HIV to Enhance Their Life (2)
The goal of this clinical trial is to learn if subcutaneous ePGT121v1-LS and VRC07-523-LS added to standard antiretroviral therapy (ART) is safe and helps improve HIV viral suppression in infants living with HIV in Mozambique and…
- Trial name
- ENABLE 2 (NCT07655141)
- Testing
- Broadly neutralizing antibody (bNAb) ePGT121v1-LS, Saline (0.9% NaCl), Broadly neutralizing antibody (bNAb) VRC07-523-LS
- Volunteers
- 73 people
- Sponsor
- Hospital Universitario 12 de Octubre
HIV I Infection
The Expand Study-Pharmacist Administered Long Acting Cabotegravir + Rilpivirine to Expand Access for People With HIV
The purpose of The EXPAND study is to develop and pilot a pharmacist led model of medication delivery. Following a co-design phase, patients may receive injections at satellite pharmacies by a licensed pharmacist.
- Trial name
- EXPAND (NCT06635421)
- Testing
- Model of care delivery for long-acting injectable ART
- Volunteers
- 164 people
- Sponsor
- MetroHealth Medical Center
HIV Infections, HBV Coinfection
Study Evaluating the Safety, in Terms of HBV Virological Control At 96 Weeks, of 2 Antiviral Treatment Relief Strategies, in Patients Co-infected with the HIV-1 and HBV Viruses
The main objective of this study is to evaluate at 96 weeks the safety with respect to hepatitis B control of 2 treatment reduction strategies for patients with previously controlled HIV-HBV co-infection on continuous triple…
- Trial name
- BI-LIGHT (NCT06338826)
- Testing
- TDF - 245mg or TAF -25mg associated to 3TC - 300mg or FTC - 200mg and a NNRTI or PI/r or INSTI, Dual therapy with 3TC in combination with DTG or ritonavir-boosted Darunavir (rDVR)
- Volunteers
- 140 people
- Sponsor
- ANRS, Emerging Infectious Diseases
Vaccination; Infection, HIV-1-infection
Triage Survey for Infectious Disease Eligibility
SWIFT-ID-101 is a single site survey study designed to assess potential participants' eligibility to screen for industry-sponsored clinical trials for diagnosis, treatment, or prevention of infectious diseases such as in the…
- Conditions
- Vaccination; Infection, HIV-1-infection, Infectious Disease
- Trial name
- NCT06492187
- Where
- United States
- Volunteers
- 10,000 people, healthy volunteers welcome
- Sponsor
- Brooklyn Clinical Research
HIV-1 Infection, HIV Reservoir
Intestinal Tissue-Resident Memory T Cells and HIV-1 Persistence During Antiretroviral Therapy
The study aims to better characterize intestinal tissue-resident memory T cells (TRM) in people living with HIV-1 receiving suppressive antiretroviral therapy (ART).
- Conditions
- HIV-1 Infection, HIV Reservoir, Antiretroviral Therapy
- Trial name
- ANRSGALT-2 (NCT07656077)
- Testing
- Colonic Mucosal Biopsies
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV
Imaging and Biopsy of People With HIV-1 Undergoing Analytic Treatment Interruption
Background: Human immunodeficiency virus (HIV) infects CD4 T cells. There is no cure for HIV. People with HIV need to take daily medications called antiretroviral therapy (ART) to control their infection.
- Trial name
- NCT05419024
- Testing
- Acute Treatment Interruption
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- National Cancer Institute (NCI)
HIV Infections
A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study)
This clinical study is testing a new medication, VH4524184, to see if it can effectively treat HIV-1 in adults who have never received treatment for their infection.
- Trial name
- NCT07202546
- Testing
- VH4524184, Emtricitabine (FTC) and tenofovir alafenamide (TAF) Fixed Dose Combination (FDC) tablets, Dolutegravir / Lamivudine (DTG/3TC)
- Where
- 123 sites in United States, Argentina and 12 more
- Volunteers
- 186 people
- Sponsor
- ViiV Healthcare
HIV Infections
Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on Oral Daily Antiretroviral Therapy
The goal of this clinical study is to compare how effective a long-acting injectable treatment of lenacapavir (LEN), teropavimab (TAB), and zinlirvimab (ZAB) versus (CAB) and rilpivirine (RPV) injections given every 8 weeks in…
- Trial name
- NCT07682961
- Testing
- Lenacapavir, Lenacapavir Tablet, Teropavimab
- Where
- 19 sites in United States, Australia and 1 more
- Volunteers
- 590 people
- Sponsor
- Gilead Sciences
HIV Seropositivity, HIV Drug Resistance
Study of the Prevalence of Transmitted HIV-1 Resistance, Viral Diversity, and Cluster Identification in Patients at the Time of HIV-1 Diagnosis
The primary objective of the study is to determine the frequency of transmission of viruses carrying at least one antiretroviral resistance mutation in all participants newly diagnosed with HIV-1
- Conditions
- HIV Seropositivity, HIV Drug Resistance, HIV Infections
- Trial name
- PRINAVIH (NCT07146529)
- Volunteers
- 30,060 people
- Sponsor
- ANRS, Emerging Infectious Diseases
HIV Infections
Pharmacokinetics, Safety, Tolerability of Dolutegravir/Rilpivirine in Pediatrics
The purpose of this study is to provide data on the pharmacokinetic (PK), safety, tolerability, efficacy and acceptability of this fixed dose combination (FDC) single tablet 2-drug regimen for virologically suppressed (HIV-1 RNA…
- Trial name
- NCT05674656
- Testing
- Dolutegravir/Rilpivirine FDC
- Where
- 8 sites in United States
- Volunteers
- 20 people
- Sponsor
- ViiV Healthcare
HIV-1-infection
Dolutegravir/Lamivudine in Treatment-Naïve Pregnant Women
Protocol Number: FH-94 Study Objetives: Primary: To evaluate the virological response to Dolutegravir/Lamivudine in naive pregnant women with HIV who are starting antiretroviral therapy and vertical transmission in exposed…
- Trial name
- PREDUAL (NCT07616739)
- Testing
- Dolutegravir/Lamivudine 50 MG-300 MG Oral Tablet [DOVATO], TDF/XTC or TAF/FTC plus Dolutegravir (XTC stand for lamivudine OR emtricitabine)
- Where
- 10 sites in Argentina, Brazil
- Volunteers
- 210 people
- Sponsor
- Fundación Huésped
HIV-1 Infection
A Phase Ⅱa Clinical Study of CL-197 Capsules
This study will evaluate the antiretroviral activity, safety and pharmacokinetics of single dose of CL-197 capsule in three dose groups administered to antiretroviral treatment-naïve adult participants with human immunodeficiency…
- Trial name
- NCT07308782
- Testing
- CL-197 capsules
- Where
- China
- Volunteers
- 24 people
- Sponsor
- Henan Genuine Biotech Co., Ltd.
HIV-1-infection
HIV Resistance, Molecular Epidemiology and New Treatment Strategies in the Eastern European Region and in Russia
Cohort based prospective monitoring of the spread of HIV drug resistance during a phase when new anti-HIV drugs are introduced.
- Trial name
- NCT06127290
- Where
- 4 sites in Germany, Italy and 2 more
- Volunteers
- 200 people
- Sponsor
- Euresist Network GEIE
Depression, Anxiety, Trauma
Psychoeducation, Relaxation, PrOblem Solving, Activation, Cognitive Coping Therapy for Adolescents and Youth in HIV Care
The proposed PROACT study will test the effectiveness of a mental health intervention (psychotherapy) for multiple common mental health conditions (depressive, anxiety and trauma symptoms) among adolescents and youth with HIV in…
- Conditions
- Depression, Anxiety, Trauma, HIV-1-infection
- Trial name
- PROACT (NCT06247527)
- Testing
- Psychoeducation, Relaxation, PrOblem solving, Activation, Cognitive coping Therapy, Standard of care
- Where
- Kenya
- Volunteers
- 600 people
- Sponsor
- University of Nairobi